Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Lotte Westerink*, Jelmer Lennart Jens Nicolai, Maarten Jacobus Postma, Job Frank Martien van Boven, Cornelis Boersma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science